Airway granulation response to lung-implantable medical devices: a concise overview

Sharyn A. Roodenburg1,2, Simon D. Pouwels3 and Dirk-Jan Slebos1,2

1Dept of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 2Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 3Dept of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Corresponding author: Sharyn Roodenburg (s.a.roodenburg@umcg.nl)

Abstract
Increasing numbers of endoscopically implantable devices are implanted in the airways, such as airway stents, one-way valves and coils, to treat both malignant and benign diseases. They significantly improve patient outcomes, but their long-term effectiveness and sustainability is hampered by the reaction of the formation of granulation tissue. Factors including procedural-related tissue injury; micro-organism presence; device-related factors, such as the material, design and sizing in relation to the airway; and patient-related factors, including genetic susceptibility, comorbidities and medication use, might all effect the severity of the tissue response and the subsequent degree of granulation tissue formation. However, research into the underlying mechanism and risk factors is scarce and therefore our knowledge is limited. Joint efforts from the scientific community, both pre-clinical and clinical, are needed to gain a deeper understanding and eventually improve the long-term treatment effectiveness of lung-implantable devices.

Introduction
Interventional pulmonology is a rapidly developing field within pulmonary medicine. Minimally invasive techniques are used to perform diagnostic and therapeutic procedures for lung diseases. Increasing numbers of endoscopically implantable devices are being placed in the airways, including a wide variety of airway stents, one-way valves and coils [1]. These implantable devices are used for both malignant (e.g. lung cancer) and benign (e.g. post-lung transplant pathology and lung volume reduction) diseases [2, 3]. They provide significant improvements in patient outcomes, but their long-term effectiveness and sustainability is hampered by the tissue reaction of the airways upon implantation. One of the most common complications associated with lung-implantable devices is the formation of granulation tissue [2, 4–6]. Granulation tissue is formed as part of the natural wound healing process and consists of accumulated inflammatory cells, newly formed connective tissue and small blood vessels (figure 1). It often presents asymptomatically, but it is also frequently associated with loss of treatment effectiveness [5, 7]. Furthermore, it is one of the most common reasons for additional bronchoscopic procedures, which form a risk and burden for the patient [5–7].

Since their introduction in the 1960s, airway stents have been widely used to manage both benign and malignant central airway stenosis, airway fistulas and post-lung transplant anastomotic complications [8]. The two main types of airway stents available are silicone and self-expandable metallic stents. All stent types are associated with a substantial risk of granulation tissue formation, but the risk varies greatly between studies. It can cause (re-)stenosis of the central airway requiring frequent additional bronchoscopic interventions. Furthermore, it is the main reason their usage is discouraged in benign diseases, especially when patients have an expected long-term survival and when other treatment options are available [2].
Both one-way valves and coils are bronchoscopic treatment options for patients suffering from severe emphysema with evident hyperinflation [9–11]. Valves and coils function through a separate mechanism of action, but both aim for lung volume reduction. Valves have a one-way mechanism allowing air to leave the treated lobe during expiration, but block air from flowing in during inspiration aiming for complete atelectasis of the treated lobe [9]. Endobronchial coils are preformed nitinol wires that regain their shape following deployment in the airways, mainly causing a local reduction in hyperinflation and decreased airway resistance [12–14]. To date, valves have been adopted into treatment guidelines where coils have only been used in clinical trials [14–19]. Clinically significant granulation tissue formation is a common finding following valve treatment [5, 6, 20, 21]. In a significant number of cases, it results in a loss of initial treatment effect due to valve dysfunction caused by the formed granulation tissue [20]. In contrast, granulation tissue formation after coil treatment has not been described. The success of all these treatments is heavily affected by the tissue response upon device implantation. However, research dedicated to unravelling the underlying mechanism and the driving forces of airway granulation tissue formation after device implantation is limited. A deeper understanding will help to improve the devices, treatments and subsequently the quality of life of the treated patients. This review will serve as an introduction into the current understanding. Furthermore, we will discuss the remaining questions and unknowns guiding future research.

**Host response to device implantation**

Implantation of any medical device causes some degree of injury to the local tissue [22]. Following this injury, an interaction between the host immune system and the implanted device will occur. The implanted device acquires a layer of host proteins forming a provisional matrix [23]. The (surface) properties of the implanted device and the severity of tissue disruption influence the types, concentrations and conformations of the absorbed proteins, which in turn influence the subsequent inflammatory response [23, 24]. The acute inflammation phase is characterised by the infiltration of neutrophils to the site of implantation [23, 25]. This phase is short-lived, usually lasting less than 1 week [23, 25]. The presence of a device (i.e. a foreign body) initiates a pro-inflammatory state attracting mononuclear cells (such as monocytes and lymphocytes), initiating the chronic inflammatory phase [23, 24, 26]. Macrophages try to phagocytose the implanted device and in an attempt to increase their phagocytic capacity they can fuse and form foreign body giant cells (FBGCs), which are described as a hallmark of the foreign body reaction [24]. However, to form FBGCs, appropriate fusion-inducing stimuli need to be present as well as a material with the appropriate adherent proteins on the surface [23]. Therefore, not all implanted devices will cause FBGC formation. The inflammatory and foreign body response attract fibroblasts and endothelial cells to the implantation site [24]. These cells deposit collagen and other extracellular matrix proteins, which form granulation tissue around the implanted device [24, 27]. Eventually, this granulation tissue matures into fibrous tissue [24]. The amount of granulation and fibrous tissue formed is dependent on the severity of the previous inflammatory response [28]. A summary of the foreign body reaction is shown in figure 2. Surprisingly, this reaction has not been studied for airway tissue upon device implantation.

**Micro-organism presence**

The implantation of airway devices is associated with an increase in microbiological colonisation [29, 30]. It has been hypothesised that micro-organism presence at the site of implantation leads to a more severe or
persistent tissue response upon device implantation causing significant granulation tissue formation [22, 27]. Two studies described a correlation between granulation tissue formation after airway stenting and airway colonisation [31, 32]. Both studies identified a correlation between airway colonisation with *Pseudomonas aeruginosa* and granulation tissue formation after airway stenting [31, 32]. One of the studies also identified a correlation between airway colonisation with *Staphylococcus aureus* and granulation tissue formation [32]. However, the findings in these studies should be interpreted with caution. Both studies used culture-based methods to identify the presence of micro-organisms. A disadvantage of culture-based methods is that the constituents of the growth medium determine which micro-organisms can be cultured. Therefore, micro-organisms that might play a role in the tissue response may be undetected. Furthermore, both studies had a small sample size and a causal relationship between micro-organism presence and granulation tissue formation cannot be determined, because the cultures were obtained when granulation tissue was already present.

Ost *et al.* studied the relationship between respiratory tract infections and granulation tissue formation after airway stenting [33]. Their multivariate analysis identified respiratory tract infections as a risk factor for granulation tissue development. However, not all patients underwent bronchoscopy at time of the respiratory tract infection. Therefore, it is unknown if granulation tissue was already present at the time of infection.

Based on these studies, no hard conclusions can be drawn on the effects of micro-organism presence on the development of granulation tissue formation. Future well-designed, prospective studies using more advanced culture methods and structured sampling are needed to identify if micro-organisms play a role in the tissue response upon device implantation in the airways, and, if so, what their contribution is.

**Device-related factors**

The airway tissue is continuously being stretched during inspiration. If the surrounding tissue is rubbing against the implant, mechanical friction occurs, which could cause repetitive injury to the tissue, mainly at the “sharper” edges of the device [7, 33, 34]. McGrath *et al.* [7] used a computer model to study stent–tissue interactions. Contact pressure change during the respiratory cycle was used as a measure for relative motion between the stent and adjacent tissue. The highest pressure change was observed at the proximal end of the stent, with areas of high pressure change also found at the distal end of the stent. In contrast, only a minor pressure change was observed in the medial portion of the stented region. These findings are in accordance with the *in vivo* situation at which granulation tissue formation is mainly observed at the stent–mucosal interface and is most frequent and/or severe at the proximal end [7, 35, 36]. The shape and design of the device and the material(s) it is composed of will likely affect the amount of friction and the amount of tissue damage. It could be speculated that devices with sharper edges or rougher surfaces cause more damage to the surrounding tissue and if friction is present this damage will be repetitive and result in (more severe) granulation tissue formation (figure 3).
Implanted airway devices almost always exert some pressure on the airway wall, which is necessary to keep the device in place. However, excessive pressure to the airway mucosa could result in impaired microcirculation, which might stimulate granulation tissue formation [37]. A computer model from McGrath et al. [7] found that wall stress was minimally affected by the insertion of an airway stent and the highest amount of wall stress was found at the distal end of the stent due to tapering of the airways, which does not correspond with in vivo observations. However, in this model only one stent size was tested. A clinical study found an association between a higher implant-to-airway size ratio and granulation tissue formation [36]. A computer model also found a positive correlation between implant-to-airway size ratios and wall stress [37]. However, in this model wall stress was not particularly high at any specific stent region, which does not correspond with the in vivo observations. Furthermore, this model found that the stiffness of the material and the stent design affected wall stress independent of the implant-to-airway size ratio [37].

None of the studies investigated the biological mechanism involved in increased mucosal-device friction and/or pressure and the development of granulation and fibrotic tissue. It is, however, tempting to speculate that these factors, especially friction, repetitively cause tissue injury accompanied by cellular damage. Cellular damage can induce the release of danger signals, named damage-associated molecular patterns (DAMPs), molecular signals which alert and activate the innate immune system to resolve the damage and danger [38, 39]. DAMPs are molecules that under physiological conditions reside intracellularly, but upon cellular damage or necrotic cell death are released into the extracellular space. Once released into the extra cellular space, DAMPs can activate pattern recognition receptors on cells of the innate immune systems, including airway epithelial cells, ultimately resulting in a local inflammatory reaction [40]. The cellular damage induced by devices implanted into the airway will induce acute DAMP release upon implantation, but DAMP release may become chronic upon friction or pressure induced by lung implants, potentially resulting in the formation of granulation and subsequently fibrotic tissue [39].

**Patient-related factors**

In contrast to the device-related factors, which remain largely the same from implantation to months and years later, patient-related factors, such as age, comorbidities and medication use, could significantly change over time. Since plasma proteins and the immune system are the main modulators of the foreign body response, factors influencing these might be the strongest influencers of the tissue response.

**Medication use**

A number of patients receiving a lung-implantable device use medications with immunomodulatory effects, such as immunosuppressives used by lung transplant patients or (inhaled) corticosteroids in patients with COPD. In the study by Shlomi et al. [41], patients using immunosuppressives after lung transplantation showed a significant lower degree of granulation tissue formation after airway stenting compared with patients not taking immunosuppressives. In contrast, Saad et al. [34] found the rate of granulation tissue formation to be equal for post-lung transplant patients and patients who underwent airway stenting for other benign causes. The main difference between these studies is that in the first, patients routinely underwent a bronchoscopic evaluation every 3 months and, in the latter, only 6 and 12 weeks after implantation and on indication. The difference in outcomes could be explained by patients with asymptomatic granulation tissue formation. To the best of our knowledge, no studies have been performed investigating the effect of corticosteroids on granulation tissue formation.
Genetic susceptibility

Abundant granulation tissue formation upon device implantation can be interpreted as “wound healing gone wrong”. A possible comparable condition is keloid scarring in skin wound healing. This is a dermal fibroproliferative disease in which there is an excessive deposition of collagen at the site of healed injury [42]. There is strong evidence that keloid formation is associated with different genetic and epigenetic factors, which is highlighted by the fact that keloid formation is more common in individuals with a nonwhite ethnicity and a positive family history of keloid formation [42]. Eom et al. [43] identified tracheal wall thickness as an independent predictor for granulation tissue formation after airway stenting in patients suffering from post-tuberculosis tracheal stenosis. This might be explained by inter-individual differences in healing responses. It is likely that for airway granulation tissue formation after device implantation individual differences in susceptibility are also present. Future studies should be directed at identifying genetic factors associated with susceptibility for the development of granulation tissue upon endoscopic device implantation, using genome-wide approaches.

Concluding remarks and future directions

In this review we have provided an overview of the factors involved in the development of granulation tissue after device implantation in the airways. The evidence for a potential key role of micro-organisms in instigating the formation of granulation tissue is minimal and mainly based on small, culture-based, retrospective studies. Future studies should investigate the presence of micro-organisms on explanted devices using a metagenomics sequencing approach to fully investigate the presence of micro-organisms in a nonbiased way, both in patients with granulation tissue and those without. We propose that, in addition to micro-organisms, DAMPs, released from lung cells damaged by the presence of a nonflexible foreign material device in a flexible and continuously dynamic airway, can also contribute to the onset of an inflammatory response, ultimately leading to the formation of granulation tissue around the implanted device. Furthermore, host factors, such as genetic susceptibility to develop airway inflammation or a more severe inflammatory response in general upon a damaging stimulus, may contribute to the development of granulation tissue [39, 44]. In addition to host factors, device-related factors, such as the physical and chemical characteristics of the device, will most certainly play a role in the reaction upon implantation. The surface characteristics of the device in particular can affect protein adsorption, cell adhesion and differentiation and, with that, affect the following inflammatory response [24].

For decades, intervention pulmonologists have been implanting devices into the airways. The development of these lung-implantable devices has provided us with new treatment opportunities and less invasive
treatment options. However, the tissue response following implementation is one of the major challenges, but our knowledge limited. Innovative attempts are being made to reduce complications, such as 3D-printed stents or bioresorbable stents [45, 46], but a better understanding of the underlying processes and factors contributing to this tissue response is urgently needed. As the number of patients treated with lung-implantable devices will likely increase with the development of new devices, this knowledge will help to guide the attempts to reduce this response. A large variety of factors can influence multiple phases of the tissue response. The complex nature of this response requires joint efforts from the scientific community to combine both pre-clinical as well as clinical evidence to gain more insights into the mechanisms and factors driving and influencing the tissue response of the airways upon device implantation. To direct future research, we propose a hypothetical model of factors that might influence the tissue response (figure 4).

Provenance: Submitted article, peer reviewed.

Conflict of interest: S.A. Roodenburg has nothing to disclose. S.D. Pouwels has nothing to disclose. D-J. Slebos reports grants or contracts, consulting fees, honoraria and travel expenses from PulmonX Corp USA; and grants or contracts, honoraria and travel expenses from PneumRX/BTG USA, outside the submitted works.

References
1 Criner GJ, Eberhardt R, Fernandez-Bussy S, et al. Interventional bronchoscopy. Am J Respir Crit Care Med 2020; 202: 29–50.
2 Guibert N, Saka H, Dutau H. Airway stenting: technological advancements and its role in interventional pulmonology. Respirology 2020; 25: 953–962.
3 Shah PL, Slebos D. Bronchoscopic interventions for severe emphysema: where are we now? Respirology 2020; 25: 972–980.
4 Murgu SD, Egressy K, Laxmanan B, et al. Central airway obstruction. Chest 2016; 150: 426–441.
5 Gompelmann D, Gerovasili V, Kontogianni K, et al. Endoscopic valve removal >180 days since implantation in patients with severe emphysema. Respiration 2018; 96: 348–354.
6 Roodenburg SA, Klooster K, Hartman JE, et al. Revision bronchoscopy after endobronchial valve treatment for emphysema: indications, findings and outcomes. Int J COPD 2021; 16: 1127–1136.
7 McGrath DJ, Thiebes AL, Cornelissen CG, et al. Evaluating the interaction of a tracheobronchial stent in an ovine in-vivo model. Biomech Model Mechanobiol. 2018; 17: 499–516.
8 Ayub A, Al-Ayoubi AM, Bhora FY. Stents for airway strictures: selection and results. J Thorac Dis 2017; 9: S116–S121.
9 Slebos D-J, Shah PL, Herth FJF, et al. Endobronchial valves for endoscopic lung volume reduction: best practice recommendations from expert panel on endoscopic lung volume reduction. Respiration 2017; 93: 138–150.
10 Slebos D-J, Ten Hacken NH, Hetzel M, et al. Endobronchial coils for endoscopic lung volume reduction: best practice recommendations from an expert panel. Respiration 2018; 96: 1–11.
11 Criner GJ, Delage A, Voelker K, et al. Improving lung function in severe heterogenous emphysema with the spiration valve system (emprove). A multicenter, open-label randomized controlled clinical trial. Am J Respir Crit Care Med 2019; 200: 1354–1362.
12 Herth FJF, Slebos DJ, Shah PL, et al. Protocol of a Randomized Controlled Study of the Pneumrx Endobronchial Coil System Versus Standard-of-Care Medical Management in the Treatment of Subjects with Severe Emphysema (ELEVATE). Respiration 2019; 98: 512–520.
13 Hartman JE, Shah PL, Sciaruba F, et al. Endobronchial coils for emphysema: dual mechanism of action on lobar residual volume reduction. Respiration 2020; 25: 1160–1166.
14 Sciaruba FC, Criner GJ, Strange C, et al. Effect of endobronchial coils vs usual care on exercise tolerance in patients with severe emphysema. JAMA 2016; 315: 2178-2189.
15 Deslée G, Mal H, Dutau H, et al. Lung volume reduction coil treatment vs usual care in patients with severe emphysema. JAMA 2016; 315: 175.
16 Shah PL, Zoumot Z, Singh S, et al. Endobronchial coils for the treatment of severe emphysema with hyperinflation (RESET): a randomised controlled trial. Lancet Respir Med 2013; 1: 233–240.
17 Zoumot Z, Kemp SV, Singh S, et al. Endobronchial coils for severe emphysema are effective up to 12 months following treatment: medium term and cross-over results from a randomised controlled trial. PLoS ONE 2015; 10: e0122656.
18 Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2020. Available from: www.goldcopd.org.
19 National Institute for Health and Care Excellence. Endobronchial valve insertion to reduce lung volume in emphysema. 2017. Available from: https://www.nice.org.uk/guidance/ipg600/chapter/3-The-procedure
